Johnson Matthey Plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Johnson Matthey Plc
The US biotech has released new positive data from two late-stage studies in the rare disease after the US FDA asked for more controlled data following an initial disappointment.
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
BioMarin teams with Skyline on gene therapies for cardiovascular disease. Myrtelle discloses licensing of gene therapy for Canavan disease from Pfizer earlier in 2021.